Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™) + M-M-R™ II and Varivax™
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Measles
Conditions
Measles, Mumps, Rubella, Varicella
Trial Timeline
Feb 1, 2008 → May 1, 2008
NCT ID
NCT00839917About Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™) + M-M-R™ II and Varivax™
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™) + M-M-R™ II and Varivax™ is a phase 3 stage product being developed by Merck for Measles. The current trial status is terminated. This product is registered under clinical trial identifier NCT00839917. Target conditions include Measles, Mumps, Rubella.
What happened to similar drugs?
4 of 17 similar drugs in Measles were approved
Approved (4) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00839917 | Phase 3 | Terminated |
Competing Products
20 competing products in Measles